- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
The Macular Degeneration (AMD) and Other Retinal Diseases market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Macular Degeneration (AMD) and Other Retinal Diseases market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Macular Degeneration (AMD) and Other Retinal Diseases global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Macular Degeneration segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Macular Degeneration (AMD) and Other Retinal Diseases include Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, and Kanghong Pharma, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Macular Degeneration (AMD) and Other Retinal Diseases market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Macular Degeneration
Diabetic Macular Edema
Diabetic Retinopathy(DR)
Retinal Vein Occlusion
Wet Age-Related Macular Degeneration (wAMD)
Dry Age-Related Macular Degeneration (dAMD)
Other
Market segment by Application, can be divided into
Hospital
Clinic
Other
Market segment by players, this report covers
Regeneron Pharmaceuticals
Bayer HealthCare
Novartis
Roche
Kanghong Pharma
Merck
Allergan
Santen Pharmaceutical
GlaxoSmithKline Pharmaceuticals
Pfizer
Acucela
Valent Pharmaceuticals
IVERIC
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Macular Degeneration (AMD) and Other Retinal Diseases product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Macular Degeneration (AMD) and Other Retinal Diseases, with revenue, gross margin and global market share of Macular Degeneration (AMD) and Other Retinal Diseases from 2019 to 2022.
Chapter 3, the Macular Degeneration (AMD) and Other Retinal Diseases competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Macular Degeneration (AMD) and Other Retinal Diseases market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Macular Degeneration (AMD) and Other Retinal Diseases research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Macular Degeneration (AMD) and Other Retinal Diseases
1.2 Classification of Macular Degeneration (AMD) and Other Retinal Diseases by Type
1.2.1 Overview: Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Type in 2021
1.2.3 Macular Degeneration
1.2.4 Diabetic Macular Edema
1.2.5 Diabetic Retinopathy(DR)
1.2.6 Retinal Vein Occlusion
1.2.7 Wet Age-Related Macular Degeneration (wAMD)
1.2.8 Dry Age-Related Macular Degeneration (dAMD)
1.2.9 Other
1.3 Global Macular Degeneration (AMD) and Other Retinal Diseases Market by Application
1.3.1 Overview: Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size & Forecast
1.5 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size and Forecast by Region
1.5.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region, (2017-2022)
1.5.3 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size and Prospect (2017-2028)
1.5.4 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size and Prospect (2017-2028)
1.5.6 South America Macular Degeneration (AMD) and Other Retinal Diseases Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Macular Degeneration (AMD) and Other Retinal Diseases Market Drivers
1.6.2 Macular Degeneration (AMD) and Other Retinal Diseases Market Restraints
1.6.3 Macular Degeneration (AMD) and Other Retinal Diseases Trends Analysis
2 Company Profiles
2.1 Regeneron Pharmaceuticals
2.1.1 Regeneron Pharmaceuticals Details
2.1.2 Regeneron Pharmaceuticals Major Business
2.1.3 Regeneron Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
2.1.4 Regeneron Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Regeneron Pharmaceuticals Recent Developments and Future Plans
2.2 Bayer HealthCare
2.2.1 Bayer HealthCare Details
2.2.2 Bayer HealthCare Major Business
2.2.3 Bayer HealthCare Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
2.2.4 Bayer HealthCare Macular Degeneration (AMD) and Other Retinal Diseases Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Bayer HealthCare Recent Developments and Future Plans
2.3 Novartis
2.3.1 Novartis Details
2.3.2 Novartis Major Business
2.3.3 Novartis Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
2.3.4 Novartis Macular Degeneration (AMD) and Other Retinal Diseases Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Novartis Recent Developments and Future Plans
2.4 Roche
2.4.1 Roche Details
2.4.2 Roche Major Business
2.4.3 Roche Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
2.4.4 Roche Macular Degeneration (AMD) and Other Retinal Diseases Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Roche Recent Developments and Future Plans
2.5 Kanghong Pharma
2.5.1 Kanghong Pharma Details
2.5.2 Kanghong Pharma Major Business
2.5.3 Kanghong Pharma Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
2.5.4 Kanghong Pharma Macular Degeneration (AMD) and Other Retinal Diseases Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Kanghong Pharma Recent Developments and Future Plans
2.6 Merck
2.6.1 Merck Details
2.6.2 Merck Major Business
2.6.3 Merck Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
2.6.4 Merck Macular Degeneration (AMD) and Other Retinal Diseases Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Merck Recent Developments and Future Plans
2.7 Allergan
2.7.1 Allergan Details
2.7.2 Allergan Major Business
2.7.3 Allergan Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
2.7.4 Allergan Macular Degeneration (AMD) and Other Retinal Diseases Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Allergan Recent Developments and Future Plans
2.8 Santen Pharmaceutical
2.8.1 Santen Pharmaceutical Details
2.8.2 Santen Pharmaceutical Major Business
2.8.3 Santen Pharmaceutical Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
2.8.4 Santen Pharmaceutical Macular Degeneration (AMD) and Other Retinal Diseases Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Santen Pharmaceutical Recent Developments and Future Plans
2.9 GlaxoSmithKline Pharmaceuticals
2.9.1 GlaxoSmithKline Pharmaceuticals Details
2.9.2 GlaxoSmithKline Pharmaceuticals Major Business
2.9.3 GlaxoSmithKline Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
2.9.4 GlaxoSmithKline Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 GlaxoSmithKline Pharmaceuticals Recent Developments and Future Plans
2.10 Pfizer
2.10.1 Pfizer Details
2.10.2 Pfizer Major Business
2.10.3 Pfizer Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
2.10.4 Pfizer Macular Degeneration (AMD) and Other Retinal Diseases Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Pfizer Recent Developments and Future Plans
2.11 Acucela
2.11.1 Acucela Details
2.11.2 Acucela Major Business
2.11.3 Acucela Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
2.11.4 Acucela Macular Degeneration (AMD) and Other Retinal Diseases Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Acucela Recent Developments and Future Plans
2.12 Valent Pharmaceuticals
2.12.1 Valent Pharmaceuticals Details
2.12.2 Valent Pharmaceuticals Major Business
2.12.3 Valent Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
2.12.4 Valent Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 Valent Pharmaceuticals Recent Developments and Future Plans
2.13 IVERIC
2.13.1 IVERIC Details
2.13.2 IVERIC Major Business
2.13.3 IVERIC Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
2.13.4 IVERIC Macular Degeneration (AMD) and Other Retinal Diseases Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13.5 IVERIC Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Macular Degeneration (AMD) and Other Retinal Diseases Players Market Share in 2021
3.2.2 Top 10 Macular Degeneration (AMD) and Other Retinal Diseases Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Macular Degeneration (AMD) and Other Retinal Diseases Players Head Office, Products and Services Provided
3.4 Macular Degeneration (AMD) and Other Retinal Diseases Mergers & Acquisitions
3.5 Macular Degeneration (AMD) and Other Retinal Diseases New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Market Share by Type (2017-2022)
4.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Application (2017-2022)
5.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Type (2017-2028)
6.2 North America Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Application (2017-2028)
6.3 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country
6.3.1 North America Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Country (2017-2028)
6.3.2 United States Macular Degeneration (AMD) and Other Retinal Diseases Market Size and Forecast (2017-2028)
6.3.3 Canada Macular Degeneration (AMD) and Other Retinal Diseases Market Size and Forecast (2017-2028)
6.3.4 Mexico Macular Degeneration (AMD) and Other Retinal Diseases Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Type (2017-2028)
7.2 Europe Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Application (2017-2028)
7.3 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country
7.3.1 Europe Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Country (2017-2028)
7.3.2 Germany Macular Degeneration (AMD) and Other Retinal Diseases Market Size and Forecast (2017-2028)
7.3.3 France Macular Degeneration (AMD) and Other Retinal Diseases Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Macular Degeneration (AMD) and Other Retinal Diseases Market Size and Forecast (2017-2028)
7.3.5 Russia Macular Degeneration (AMD) and Other Retinal Diseases Market Size and Forecast (2017-2028)
7.3.6 Italy Macular Degeneration (AMD) and Other Retinal Diseases Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Type (2017-2028)
8.2 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Application (2017-2028)
8.3 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region
8.3.1 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Region (2017-2028)
8.3.2 China Macular Degeneration (AMD) and Other Retinal Diseases Market Size and Forecast (2017-2028)
8.3.3 Japan Macular Degeneration (AMD) and Other Retinal Diseases Market Size and Forecast (2017-2028)
8.3.4 South Korea Macular Degeneration (AMD) and Other Retinal Diseases Market Size and Forecast (2017-2028)
8.3.5 India Macular Degeneration (AMD) and Other Retinal Diseases Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Macular Degeneration (AMD) and Other Retinal Diseases Market Size and Forecast (2017-2028)
8.3.7 Australia Macular Degeneration (AMD) and Other Retinal Diseases Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Type (2017-2028)
9.2 South America Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Application (2017-2028)
9.3 South America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country
9.3.1 South America Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Country (2017-2028)
9.3.2 Brazil Macular Degeneration (AMD) and Other Retinal Diseases Market Size and Forecast (2017-2028)
9.3.3 Argentina Macular Degeneration (AMD) and Other Retinal Diseases Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Type (2017-2028)
10.2 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Application (2017-2028)
10.3 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country
10.3.1 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Country (2017-2028)
10.3.2 Turkey Macular Degeneration (AMD) and Other Retinal Diseases Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Diseases Market Size and Forecast (2017-2028)
10.3.4 UAE Macular Degeneration (AMD) and Other Retinal Diseases Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Macular Degeneration (AMD) and Other Retinal Diseases Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million) by Region (2017-2022)
Table 5. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Region (2023-2028)
Table 6. Regeneron Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 7. Regeneron Pharmaceuticals Major Business
Table 8. Regeneron Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
Table 9. Regeneron Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Bayer HealthCare Corporate Information, Head Office, and Major Competitors
Table 11. Bayer HealthCare Major Business
Table 12. Bayer HealthCare Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
Table 13. Bayer HealthCare Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Novartis Corporate Information, Head Office, and Major Competitors
Table 15. Novartis Major Business
Table 16. Novartis Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
Table 17. Novartis Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Roche Corporate Information, Head Office, and Major Competitors
Table 19. Roche Major Business
Table 20. Roche Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
Table 21. Roche Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Kanghong Pharma Corporate Information, Head Office, and Major Competitors
Table 23. Kanghong Pharma Major Business
Table 24. Kanghong Pharma Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
Table 25. Kanghong Pharma Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Merck Corporate Information, Head Office, and Major Competitors
Table 27. Merck Major Business
Table 28. Merck Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
Table 29. Merck Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Allergan Corporate Information, Head Office, and Major Competitors
Table 31. Allergan Major Business
Table 32. Allergan Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
Table 33. Allergan Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Santen Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 35. Santen Pharmaceutical Major Business
Table 36. Santen Pharmaceutical Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
Table 37. Santen Pharmaceutical Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. GlaxoSmithKline Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 39. GlaxoSmithKline Pharmaceuticals Major Business
Table 40. GlaxoSmithKline Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
Table 41. GlaxoSmithKline Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Pfizer Corporate Information, Head Office, and Major Competitors
Table 43. Pfizer Major Business
Table 44. Pfizer Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
Table 45. Pfizer Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Acucela Corporate Information, Head Office, and Major Competitors
Table 47. Acucela Major Business
Table 48. Acucela Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
Table 49. Acucela Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Valent Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 51. Valent Pharmaceuticals Major Business
Table 52. Valent Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
Table 53. Valent Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. IVERIC Corporate Information, Head Office, and Major Competitors
Table 55. IVERIC Major Business
Table 56. IVERIC Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
Table 57. IVERIC Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 58. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 59. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 60. Breakdown of Macular Degeneration (AMD) and Other Retinal Diseases by Company Type (Tier 1, Tier 2 and Tier 3)
Table 61. Macular Degeneration (AMD) and Other Retinal Diseases Players Head Office, Products and Services Provided
Table 62. Macular Degeneration (AMD) and Other Retinal Diseases Mergers & Acquisitions in the Past Five Years
Table 63. Macular Degeneration (AMD) and Other Retinal Diseases New Entrants and Expansion Plans
Table 64. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million) by Type (2017-2022)
Table 65. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Share by Type (2017-2022)
Table 66. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Forecast by Type (2023-2028)
Table 67. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Application (2017-2022)
Table 68. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Forecast by Application (2023-2028)
Table 69. North America Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Type (2017-2022) & (USD Million)
Table 70. North America Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Type (2023-2028) & (USD Million)
Table 71. North America Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Application (2017-2022) & (USD Million)
Table 72. North America Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Application (2023-2028) & (USD Million)
Table 73. North America Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Country (2017-2022) & (USD Million)
Table 74. North America Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Country (2023-2028) & (USD Million)
Table 75. Europe Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Type (2017-2022) & (USD Million)
Table 76. Europe Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Type (2023-2028) & (USD Million)
Table 77. Europe Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Application (2017-2022) & (USD Million)
Table 78. Europe Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Application (2023-2028) & (USD Million)
Table 79. Europe Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Country (2017-2022) & (USD Million)
Table 80. Europe Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Country (2023-2028) & (USD Million)
Table 81. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Type (2017-2022) & (USD Million)
Table 82. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Type (2023-2028) & (USD Million)
Table 83. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Application (2017-2022) & (USD Million)
Table 84. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Application (2023-2028) & (USD Million)
Table 85. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Region (2017-2022) & (USD Million)
Table 86. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Region (2023-2028) & (USD Million)
Table 87. South America Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Type (2017-2022) & (USD Million)
Table 88. South America Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Type (2023-2028) & (USD Million)
Table 89. South America Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Application (2017-2022) & (USD Million)
Table 90. South America Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Application (2023-2028) & (USD Million)
Table 91. South America Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Country (2017-2022) & (USD Million)
Table 92. South America Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Country (2023-2028) & (USD Million)
Table 93. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Type (2017-2022) & (USD Million)
Table 94. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Type (2023-2028) & (USD Million)
Table 95. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Application (2017-2022) & (USD Million)
Table 96. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Application (2023-2028) & (USD Million)
Table 97. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Country (2017-2022) & (USD Million)
Table 98. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Macular Degeneration (AMD) and Other Retinal Diseases Picture
Figure 2. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Type in 2021
Figure 3. Macular Degeneration
Figure 4. Diabetic Macular Edema
Figure 5. Diabetic Retinopathy(DR)
Figure 6. Retinal Vein Occlusion
Figure 7. Wet Age-Related Macular Degeneration (wAMD)
Figure 8. Dry Age-Related Macular Degeneration (dAMD)
Figure 9. Other
Figure 10. Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Application in 2021
Figure 11. Hospital Picture
Figure 12. Clinic Picture
Figure 13. Other Picture
Figure 14. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 15. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Forecast (2017-2028) & (USD Million)
Figure 16. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Region (2017-2028)
Figure 17. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Region in 2021
Figure 18. North America Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. Europe Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. South America Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million) and Growth Rate (2017-2028)
Figure 22. Middle East and Africa Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million) and Growth Rate (2017-2028)
Figure 23. Macular Degeneration (AMD) and Other Retinal Diseases Market Drivers
Figure 24. Macular Degeneration (AMD) and Other Retinal Diseases Market Restraints
Figure 25. Macular Degeneration (AMD) and Other Retinal Diseases Market Trends
Figure 26. Regeneron Pharmaceuticals Recent Developments and Future Plans
Figure 27. Bayer HealthCare Recent Developments and Future Plans
Figure 28. Novartis Recent Developments and Future Plans
Figure 29. Roche Recent Developments and Future Plans
Figure 30. Kanghong Pharma Recent Developments and Future Plans
Figure 31. Merck Recent Developments and Future Plans
Figure 32. Allergan Recent Developments and Future Plans
Figure 33. Santen Pharmaceutical Recent Developments and Future Plans
Figure 34. GlaxoSmithKline Pharmaceuticals Recent Developments and Future Plans
Figure 35. Pfizer Recent Developments and Future Plans
Figure 36. Acucela Recent Developments and Future Plans
Figure 37. Valent Pharmaceuticals Recent Developments and Future Plans
Figure 38. IVERIC Recent Developments and Future Plans
Figure 39. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Share by Players in 2021
Figure 40. Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 41. Global Top 3 Players Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share in 2021
Figure 42. Global Top 10 Players Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share in 2021
Figure 43. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 44. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Share by Type in 2021
Figure 45. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share Forecast by Type (2023-2028)
Figure 46. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Share by Application in 2021
Figure 47. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share Forecast by Application (2023-2028)
Figure 48. North America Macular Degeneration (AMD) and Other Retinal Diseases Sales Market Share by Type (2017-2028)
Figure 49. North America Macular Degeneration (AMD) and Other Retinal Diseases Sales Market Share by Application (2017-2028)
Figure 50. North America Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Country (2017-2028)
Figure 51. United States Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Canada Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Mexico Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Europe Macular Degeneration (AMD) and Other Retinal Diseases Sales Market Share by Type (2017-2028)
Figure 55. Europe Macular Degeneration (AMD) and Other Retinal Diseases Sales Market Share by Application (2017-2028)
Figure 56. Europe Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Country (2017-2028)
Figure 57. Germany Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. France Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. United Kingdom Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Russia Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Italy Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Sales Market Share by Type (2017-2028)
Figure 63. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Sales Market Share by Application (2017-2028)
Figure 64. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Region (2017-2028)
Figure 65. China Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Japan Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. South Korea Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. India Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Southeast Asia Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Australia Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. South America Macular Degeneration (AMD) and Other Retinal Diseases Sales Market Share by Type (2017-2028)
Figure 72. South America Macular Degeneration (AMD) and Other Retinal Diseases Sales Market Share by Application (2017-2028)
Figure 73. South America Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Country (2017-2028)
Figure 74. Brazil Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Argentina Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Middle East and Africa Macular Degeneration (AMD) and Other Retinal Diseases Sales Market Share by Type (2017-2028)
Figure 77. Middle East and Africa Macular Degeneration (AMD) and Other Retinal Diseases Sales Market Share by Application (2017-2028)
Figure 78. Middle East and Africa Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Country (2017-2028)
Figure 79. Turkey Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. Saudi Arabia Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 81. UAE Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 82. Methodology
Figure 83. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
